IP Library Granted Patent US 11,761,960
Granted Patent B2
US 11,761,960 · App. 16/607,762 · Granted Sep 19, 2023

CD24

Inventors: Carole Brosseau (Coueron, FR); Maxim Durand (Blacy, FR); Antoine Magnan (Nantes, FR); Sophie Brouard (Suće-sur-Erdre, FR)
Assignees: UNIVERSITE DE NANTES; INSTITUT NATIONALE DE LE SANTE ET DE LA RECHERCHE MEDICALE; CHU NANTES
G01N33/56966G01N33/5052
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,761,960
App. No.
16/607,762
Granted
Sep 19, 2023
Kind
B2
Abstract

The present invention relates to an in vitro method for determining the risk of occurrence of chronic lung graft dysfunction in a human subject comprising: a) measuring the level of CD9 + B cells in a blood sample of the subject, b) comparing the level of CD9 + B cells measured at step a) with one or more reference values of the level of CD9 + B cells, and c) determining the risk of occurrence of chronic lung graft dysfunction in the said subject from the comparison performed at step b).

Claims (7)

1. A method of preventing development of chronic lung graft dysfunction or treating chronic lung graft dysfunction in a lung transplant subject comprising:

a) measuring the level of CD9 + B cells in a blood sample of the lung transplant subject,

and

b) administering a preventive or therapeutic immunosuppressive treatment to the lung transplant subject when the level of CD9 + B cells in the sample is lower than that of a reference value based on lung transplant subjects who did not reject a lung graft; wherein the amount of the immunosuppressive treatment prevents the development of chronic lung graft dysfunction or treats chronic lung graft dysfunction.

2. The method according to claim 1 , wherein step a) is performed with a method further comprising measuring the level of CD24 hi CD38 hi B cells from the blood sample of the lung transplant subject.

3. The method according to claim 2 , wherein step a) is performed with a kit comprising one or more reagents for detecting or quantifying CD9 B cells in the blood sample of the lung transplant subject and further one or both of CD24 and CD38 B cells in the blood sample of the lung transplant subject.

4. The method according to claim 1 , wherein step a) is performed with a kit comprising one or more reagents for detecting or quantifying CD9 B cells in the blood sample of the lung transplant subject.

Assignments (2)
MERGER Recorded Sep 7, 2023
From: UNIVERSITE DE NANTES
To: NANTES UNIVERSITE
Reel/Frame 064824/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2019
From: BROSSEAU, CAROLE; DURAND, MAXIM; MAGNAN, ANTOINE; BROUARD, SOPHIE
To: UNIVERSITE DE NANTES; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); CHU NANTES
Reel/Frame 051264/0520 →
Priority Claims (1)
EP 17305479 · Apr 28, 2017 · regional
Continuity (1)
Related Publication 20200057064A1 · Feb 20, 2020